Publications by authors named "Nathan A Ona"
Current clinical strategies for the delivery of pulmonary therapeutics to the lung are primarily targeted to the upper portions of the airways, such as treatment with nebulized instillation and inhalation. However, targeted delivery to the lower regions of the lung is necessary for the treatment of parenchymal lung injury and disease. Here, we show the development of an mRNA therapeutic for the lower lung in mice using one-component Ionizable Amphiphilic Janus Dendrimers as a delivery vehicle.
View Article and Find Full Text PDFNucleoside-modified mRNA-LNP vaccines have revolutionized vaccine development against infectious pathogens due to their ability to elicit potent humoral and cellular immune responses. In this article, we present the results of the first norovirus vaccine candidate employing mRNA-LNP platform technology. The mRNA-LNP bivalent vaccine encoding the major capsid protein VP1 from GI.
View Article and Find Full Text PDFScreening Libraries to Discover Molecular Design Principles for the Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers Derived from Plant Phenolic Acids.
Pharmaceutics
May 2023
Article Synopsis
- The development of COVID-19 vaccines relied heavily on viral and synthetic vectors, particularly lipid nanoparticles (LNPs) that deliver mRNA effectively.
- LNPs, made of specific lipid components, co-assemble with mRNA using microfluidic technology and are pivotal in the vaccine formulations by BioNTech/Pfizer and Moderna.
- A new methodology using ionizable multifunctional amphiphilic Janus dendrimers (IAJDs) enables targeted mRNA delivery through uniquely designed monodisperse nanoparticles, simplifying vaccine production and potentially lowering costs while maintaining effectiveness.